Progression-free survival results from BOLERO-1 trial

Bookmark and Share
Published: 12 Dec 2014
Views: 3094
Prof Sara Hurvitz - University of California, Los Angeles, USA

At a press conference at SABCS 2014, Prof Hurvitz discusses the results of  phase III Breast Cancer Trials of Oral Everolimus-1 (BOLERO-1) study.

This was a multicentre trial examining the effects of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 advanced breast cancer.

Read the news story or watch the interview for more.